LYZ and breast cancer: However, we would like to highlight that there are a few studies assessing more clinically relevant biomarkers in BC studies, like neutrophil/lymphocyte surface markers, NK cell cytotoxicity [18], neutrophil oxidative burst [15,16], neutrophil functional capacity, salivary lysozyme release [14], but the amount of them is not enough to include in a meta-analysis.